A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
Highlights from AAM's Generic & Biosimilar Medicines Savings Report
- Total Generic and Biosimilar Savings for 2022: $408 billion
- Total Generic and Biosimilar Savings for Past 10 years: more than $2.9 trillion
- Total Generic and Biosimilar Savings in Medicare for 2022: $130 Billion
- Total Generic and Biosimilar Savings in Commercial Plans for 2022: $194 Billion
- Generics represent 90% of prescriptions filled but only 17.5% of prescription drug spending
- Generics represent less than 2% of all health care spending
Source: AAM, Generic and Biosimilar Drugs Generate $408 Billion in Savings For America’s Patients and Health-Care System in 2022, September 6, 2023 - https://accessiblemeds.org/resources/press-releases/generic-biosimilar-drugs-ge…
ACO Performance Case Studies
*By signing up for this offer you agree to receive the Accountable Care bulletin and the HealthExecWire news release bulletin.
Accountable Care
Offerings
Value-Based Payments
Offerings
Analytics
Offerings
Population Health
Offerings
Payers & Providers
Offerings